N-(3-Chloro-4-fluorophenyl)-6-(3-chloropropoxy)-7-methoxyquinazolin-4-amine, 95.0%, 250mg

1-Octen-3-ol; 98%, 95.0%, 500g

(E)-(((1-Cyano-2-ethoxy-2-oxoethylidene)amino)oxy)tri(pyrrolidin-1-yl)phosphonium hexafluorophosphate(V), 95.0%, 25g

2,4-Difluoro-3-iodoaniline, 97.0%, 1g

4-Hydroxybutanal (exists as tautomeric mixture withTetrahydrofuran-2-ol), 95.0%, 50mg

CompactDry X-SA, 240 stuks

Oxion Inverso OX.2003-PLPH with LWD Plan phase 10x/20x/40x objectives

2-(1-Benzylpiperidin-4-yl)-2,3-dihydro-4H-thiochromen-4-one, 5mg

2-methyl-2H-chromene-3-carbaldehyde, 5g

methyl 5-methyl-1H-imidazole-4-carboxylate hydrochloride, 95.0%, 1g

1-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidine, 97%, 1g

Ticlopidine Hydrochloride>98.0%(HPLC)(N)5g

Ethyl 2-(4-formylphenyl)acetate, 95.0%, 250mg